Blood Screening Market - Global Forecast 2025-2032

Blood screening plays a pivotal role in supporting healthcare systems through early disease detection and safe transfusions. Senior decision-makers benefit from a clear understanding of shifts in the blood screening market to inform operational improvements and optimize patient outcomes.

Market Snapshot: Blood Screening Market Overview

The blood screening market grew from USD 5.31 billion in 2024 to USD 5.79 billion in 2025, with a compound annual growth rate (CAGR) projected at 9.06%. By 2032, the market is expected to reach USD 10.64 billion. This advancement is underpinned by global public health initiatives, ongoing diagnostic innovation, and increasing prioritization of safety measures in transfusions. Senior leaders are responding to expanded testing capabilities and evolving regulatory frameworks that shape future adoption and growth potential across diverse regions.

Scope & Segmentation of the Blood Screening Market

• Test Types: Screening includes Hepatitis B, Hepatitis C, HIV, and Syphilis, highlighting critical focus areas for transfusion safety and public health monitoring in both developed and emerging markets.
• Technologies: Utilized testing technologies encompass chemiluminescence, flow cytometry, immunoassays (such as enzyme-linked immunosorbent assay, chemiluminescence immunoassay, and radioimmunoassay), as well as molecular diagnostics including isothermal amplification, next generation sequencing, and polymerase chain reaction to address a growing range of clinical needs.
• End Users: Blood banks, clinics, diagnostic laboratories, and hospitals each contribute to screening workflows and protocols, reflecting distributed responsibilities across the care continuum.
• Sample Types: Diagnostic protocols are supported by plasma, serum, and whole blood, broadening the applicability of screening initiatives.
• Testing Modes: Lab-based and point-of-care testing modes provide adaptability for rapidly changing healthcare environments, supporting different operational and response demands.
• Regions Covered: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland; United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel; South Africa, Nigeria, Egypt, Kenya), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan) highlight varied regulatory requirements and technology adoption rates across key global healthcare markets.
• Leading Companies: Organizations driving product development and distribution include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc., Grifols S.A., Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics Inc., Hologic Inc., and Terumo BCT Inc.

Key Takeaways for Senior Decision-Makers

• Advanced diagnostics are central to meeting evolving healthcare protocols and regulatory mandates, which increases the need for strategic investment in scalable technologies.
• The integration of molecular and immunoassay testing platforms is driving efficiency and enhances the detection of diverse pathogens within both centralized and decentralized healthcare settings.
• Collaboration among manufacturers, clinical stakeholders, and regulatory bodies supports harmonized standards, knowledge exchange, and continuous innovation for assay development.
• Effective supply chain management—especially in the face of shifting trade environments and consumable sourcing—requires adaptive frameworks and robust contingency planning.
• Differentiated adoption patterns due to regional healthcare policies and market maturity highlight the importance of targeted, region-specific strategies in implementation and investment.

Assessing Tariff Impact on Blood Screening Supply Chains

The additional tariffs introduced by the United States in 2025 on diagnostic devices and consumables prompted visible pressures on supply chains. In response, diagnostic companies have diversified sourcing strategies and increased contract manufacturing to manage risks and contain cost variations. Laboratories adjusted by optimizing inventories and investing in analytics, underscoring the importance of flexible operations and resilience in maintaining supply chain continuity across the ecosystem.

Methodology & Data Sources

This report is grounded in interviews with laboratory leaders, clinical pathologists, procurement professionals, and regulatory experts. Data is supplemented by a thorough review of academic research, industry whitepapers, and trusted business databases. Quantitative modeling and cross-validation support robust, actionable insights for decision-makers.

Why This Report Matters

• Delivers a comprehensive analysis of technology evolution, changing regulations, and operational strategies to inform evidence-based growth decisions for healthcare leaders.
• Clarifies the impact of regional shifts and policy developments on supply chains, investment approaches, and targeted product development.
• Enables informed action by highlighting collaborative networks, digital transformation opportunities, and best practices for deploying new technologies in the blood screening market.

Conclusion

Ongoing innovation, strategic partnerships, and investments in healthcare infrastructure continue to shape the blood screening field. Senior leaders can apply these insights for agile strategy development, improved market navigation, and better outcomes across healthcare networks.